FDA Panel Votes In Favor of Replimune’s Melanoma Treatment
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 6.
Source diversity sample: FirstWord Pharma · Barron's · qz.com · Yahoo Finance · STAT · Fierce Biotech · Reuters · wsj.com.
How this dossier is built: methodology · AI policy · corrections.
Who reported it (9)
- Replimune's oncolytic immunotherapy clears FDA panel despite trial flaws FirstWord Pharma · 18h ago
- This Biotech Stock Is Soaring 132% After Key FDA Panel Vote on Skin Cancer Treatment Barron's · 18h ago
- FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote qz.com · 18h ago
- REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome Yahoo Finance · 18h ago
- FDA expert committee votes in favor of Replimune’s melanoma treatment STAT · 18h ago
- Replimune’s twice-rejected melanoma drug prevails in FDA adcomm Fierce Biotech · 18h ago
- Why Is REPL Stock Soaring 127% After Hours Today? Yahoo Finance · 18h ago
- US FDA advisers back Replimune skin cancer drug trial data Reuters · 18h ago
- FDA Panel Votes In Favor of Replimune’s Melanoma Treatment wsj.com · 18h ago
The story so far
"FDA Panel Votes In Favor of Replimune’s Melanoma Treatment" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by Archynetys so far.
Outlets currently covering the story include STAT, Fierce Biotech, Yahoo Finance and Reuters. Archynetys measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by Archynetys's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by Archynetys's extractive engine from coverage metadata only — no AI-written claims. Updated 7h ago.
The obvious questions
Why is "FDA Panel Votes In Favor of Replimune’s Melanoma Treatment" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst Archynetys classifies as a trend.
How does Archynetys measure this trend?
Archynetys scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
More cases reported in cyclospora outbreak not linked to lettuce: FDA data
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Cyclospora and salmonella outbreaks raise concerns about U.S. food safety
7 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
8 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Over 12,000 pounds of bacon recalled. See affected products
Two major food recalls have consumers checking their fridges and medicine cabinets.
The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has issued a nationwide recall of levothyroxine sodium tablets due to reports of the medication being subpotent.
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.